The Silk Vista Baby: Initial experience and report of two cases

Bhogal, Pervinder; Wong, Ken; Uff, Christopher; Wadley, John; Makalanda, Hegoda Levansri Dilrukshan

doi:10.1177/1591019919839196

Cited by 15 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immediately after stent deployment, 8 aneurysms (18.6%) were classified as completely occluded (O'Kelly Marotta grading system [OKM] D), 5 (11.6%) were near complete occlusion (OKM C), 4 (9.3%) showed incomplete filling (OKM B), and 26 (60.4%) showed complete filling (OKM A). Longer term follow-up data are awaited and in the only other available publication regarding the Silk Vista Baby both aneurysms were completely occluded by follow-up [36]. The results of the present study are very similar with similar rates of occlusion when compared to the FRED Jnr (79.2% p48MW vs. 78% FRED Jnr) and similar rates of complication.…”

Section: Discussionsupporting

confidence: 75%

“…It is of note that the authors reported no branch occlusions or significant caliber reductions in the stented vessels although this remains of concern [18, 33,34]. Early results on the Silk Vista Baby device have also recently been published [35,36]. Martinez-Galdámez et al [35] recently reported the results of a multicenter study involving 41 patients (28 female, average age 50.5 years) with 43 aneurysms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The p48MW Flow Diverter—Initial Human Experience

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background and Purpose The use of flow diverters to treat aneurysms arising from small caliber parent vessels has been reported. This article reports the results of the first in experiences with the p48MW (p48 Movable Wire) in humans, a device specifically designed to target vessels 1.75-3 mm in diameter. Methods This monocentric study retrospectively reviewed the prospectively maintained database to identify all patients treated with the p48MW device between January 2017 and January 2019 at this institution. Patient demographics, aneurysm characteristics, angiographic and clinical follow-up were recorded as well as complications. Results A total of 25 patients (20 female) with an average age of 55 ± 12.9 years (range 34-84) with 25 aneurysms were identified. The majority of the aneurysms was located in the anterior circulation (19/25, 76%). The average aneurysm dome width was 3.98 ± 3.6 mm (range 1.2-13 mm). Complete occlusion was seen in 18/24 (75%) aneurysms with neck remnants in 1/24 (4.2%) and continued aneurysm filling seen in the remaining cases (5/24, 20.8%). Adequate occlusion was seen in 79.2% of aneurysms (Raymond Roy Classification [RRC] grade I or II) during the follow-up period. There was a single technical complication with inappropriate deployment of the first p48MW. There was a single clinical complication (4%); however, the patient made a complete recovery (modified Rankin Scale [mRS] 0) and one patient died secondary to uncontrollable status epilepticus following acute subarachnoid hemorrhage unrelated to the treatment. Conclusion The p48MW is safe and effective for the treatment of aneurysms including those arising from distal vessels.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

The p48MW Flow Diverter—Initial Human Experience

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…We noted an improvement in terms of implant radio-opacity and visibility, which according to our experience facilitates the deployment of the stent itself. The LVIS EVO uses DFT technology to optimise visualisation and is similar in this regard to the Acandis Accero, 20 the Silk Vista Baby [21][22][23] and the p48. 24,25 In our series there was no evidence of incomplete aneurysmal neck coverage or compromised stent/ vessel relationship which is a well-known limitation of braided-cell designed stents.…”

Section: Discussionmentioning

confidence: 99%

Endovascular treatment of patients with intracranial aneurysms: feasibility and successful employment of a new low profile visible intraluminal support (LVIS) EVO stent

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background and purpose Low-profile self-expandable stents have increased the number of intracranial aneurysms treated by endovascular means. The new low-profile visible intraluminal support device LVIS EVO (Microvention), the successor of LVIS Jr, is a self-expandable and retrievable microstent system, designed for implantation into intracranial arteries with a diameter up to 2.0 mm. In this retrospective study we aimed to elucidate the technical feasibility and clinical safety of the novel LVIS EVO stent for stent-assisted coil embolisation of intracranial aneurysms. Materials and methods A single centre technical report of the first six consecutive cases of stent-assisted coil embolisation with the novel LVIS EVO stent for the treatment of unruptured or recanalised intracranial aneurysms. Records were made of basic demographics, aneurysmal characteristics, device properties and related technical details, adverse events, clinical outcomes and occlusion rates on available radiological follow-up. Results Six LVIS EVO devices were successfully implanted in all subjects to treat a total number of six intracranial aneurysms. No device-related intraprocedural complications were seen. At early clinical follow-up six out of six (100%) patients had a modified Ranking score of 0–1. Early angiographic and cross-sectional radiological follow-up, available in five out of six (83.3%) of the patients confirmed unchanged aneurysmal occlusion rates. A minor, transitory neurological deficit was recorded in one of the six (16.6%) patients. Mortality was 0%. Conclusions Preliminary experience in this subset of our patients confirms a notably improved technical behaviour of the novel LVIS EVO stent system when compared to its ancestor LVIS Jr. The enhanced visibility of the stent and the refined delivery/retrieval capabilities of the stent further increase the safety margins of the devices profile, especially in cases of tortuous anatomy.

show abstract

“…1 Although the main indication is wide-neck unruptured aneurysms arising from the paraclinoid or supraclinoid segments, advancements in FD technology developed in recent years have enabled a broadening of the indications, with treatment in smaller caliber vessels and in distal locations now feasible. [2][3][4][5] One of the main changes to the procedural set-up has been the use of triaxial systems which occurred as a consequence of the fact that nearly all available FDs require the use of 0.027 inch (0.69) microcatheters for the deployment of a device designed for a 4 or 5 mm vessel. [6][7][8] The complexity of the procedure is secondary to vessel tortuosity, where distal navigation of the microcatheter can be cumbersome, requiring robust coaxial constructions, 9 10 or the opening/apposition of the braid may be affected.…”

Section: Introductionmentioning

confidence: 99%

First multicenter experience using the Silk Vista flow diverter in 60 consecutive intracranial aneurysms: technical aspects

Martínez‐Galdámez

Onal

Cohen³

et al. 2021

J NeuroIntervent Surg

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this study was to assess the technical success and procedural safety of the new Silk Vista device (SV) by evaluating the intraprocedural and periprocedural complication rate after its use in several institutions worldwide.MethodsThe study involved a retrospective review of multicenter data regarding a consecutive series of patients with intracranial aneurysms, treated with the SV between September 2020 and January 2021. Clinical, intra/periprocedural and angiographic data, including approach, materials used, aneurysm size and location, device/s, technical details and initial angiographic aneurysm occlusion, were analyzed.Results60 aneurysms were treated with SV in 57 procedures. 66 devices were used, 3 removed and 63 implanted. The devices opened instantaneously in 60 out of 66 (91%) cases and complete wall apposition was achieved in 58 out of 63 (92%) devices implanted. In 4 out of 66 (6%) devices a partial opening of the distal end occurred, and in 5 (8%) devices incomplete apposition was reported. There were 3 (5%) intraprocedural thromboembolic events managed successfully with no permanent neurological morbidity, and 4 (7%) postprocedural events. There was no mortality in this study. The initial occlusion rates in the 60 aneurysms were as follows: O’Kelly–Marotta (OKM) A in 34 (57%) cases, OKM B in 15 (25%) cases, OKM C in 6 (10%) cases, and OKM D in 5 (8%) cases.ConclusionsOur study demonstrated that the use of the new flow diverter Silk Vista for the treatment of intracranial aneurysms is feasible and technically safe.

show abstract

The Silk Vista Baby: Initial experience and report of two cases

Cited by 15 publications

References 39 publications

The p48MW Flow Diverter—Initial Human Experience

The p48MW Flow Diverter—Initial Human Experience

Endovascular treatment of patients with intracranial aneurysms: feasibility and successful employment of a new low profile visible intraluminal support (LVIS) EVO stent

First multicenter experience using the Silk Vista flow diverter in 60 consecutive intracranial aneurysms: technical aspects

Contact Info

Product

Resources

About